Wall Street Analysts Predict a 156.09% Upside in Beyond (BYON): Here's What You Should Know — Positive
BYON Zacks Investment Research — May 13, 2025The consensus price target hints at a 156.1% upside potential for Beyond (BYON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict a 36.55% Upside in Ardent Health Partners, Inc. (ARDT): Here's What You Should Know — Positive
ARDT Zacks Investment Research — May 13, 2025The mean of analysts' price targets for Ardent Health Partners, Inc. (ARDT) points to a 36.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
How Much Upside is Left in Clearfield (CLFD)? Wall Street Analysts Think 26.51% — Positive
CLFD Zacks Investment Research — May 13, 2025The mean of analysts' price targets for Clearfield (CLFD) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe ClearPoint Neuro (CLPT) Could Rally 102.86%: Here's is How to Trade — Positive
CLPT Zacks Investment Research — May 13, 2025The average of price targets set by Wall Street analysts indicates a potential upside of 102.9% in ClearPoint Neuro (CLPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade — Positive
COGT Zacks Investment Research — May 13, 2025The consensus price target hints at a 224.4% upside potential for Cogent Biosciences (COGT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can Easterly Government Properties (DEA) Climb 35.04% to Reach the Level Wall Street Analysts Expect? — Positive
DEA Zacks Investment Research — May 13, 2025The consensus price target hints at a 35% upside potential for Easterly Government Properties (DEA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Intapp (INTA) Could Rally 26.09%: Here's is How to Trade — Positive
INTA Zacks Investment Research — May 13, 2025The mean of analysts' price targets for Intapp (INTA) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Can Honest (HNST) Climb 40.83% to Reach the Level Wall Street Analysts Expect? — Positive
HNST Zacks Investment Research — May 13, 2025The mean of analysts' price targets for Honest (HNST) points to a 40.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Kemper (KMPR) Have the Potential to Rally 25.46% as Wall Street Analysts Expect? — Positive
KMPR Zacks Investment Research — May 13, 2025The average of price targets set by Wall Street analysts indicates a potential upside of 25.5% in Kemper (KMPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect? — Positive
MNMD Zacks Investment Research — May 13, 2025The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 279.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think Centrus Energy (LEU) Could Surge 56.61%: Read This Before Placing a Bet — Positive
LEU Zacks Investment Research — May 13, 2025The mean of analysts' price targets for Centrus Energy (LEU) points to a 56.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe 10x Genomics (TXG) Could Rally 55.85%: Here's is How to Trade — Positive
TXG Zacks Investment Research — May 13, 2025The average of price targets set by Wall Street analysts indicates a potential upside of 55.9% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 51.77% Upside in Inspired Entertainment (INSE): Can the Stock Really Move This High? — Positive
INSE Zacks Investment Research — May 13, 2025The consensus price target hints at a 51.8% upside potential for Inspired Entertainment (INSE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High? — Positive
TECX Zacks Investment Research — May 13, 2025The consensus price target hints at a 258.5% upside potential for Tectonic Therapeutic, Inc. (TECX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 41.11% Upside in Treace Medical Concepts (TMCI): Can the Stock Really Move This High? — Positive
TMCI Zacks Investment Research — May 13, 2025The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Treace Medical Concepts (TMCI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34% — Positive
SYRE Zacks Investment Research — May 13, 2025The average of price targets set by Wall Street analysts indicates a potential upside of 258.3% in Spyre Therapeutics (SYRE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
UPST vs. AFRM: Which AI-Powered Fintech Stock Offers Better Growth? — Neutral
AFRM UPST Zacks Investment Research — May 13, 2025Which AI-powered fintech stock, Upstart Holdings or Affirm Holdings, offers the better investment opportunity at present? Let's find out.
PANW, CRWD & Cybersecurity: "We're at the Starting Line" of A.I. Security Race — Positive
CRWD PANW Schwab Network — May 13, 2025Paul Powers says we're just seeing the start of A.I. integration into cybersecurity.
Plug Power Q1 Loss Wider Than Expected, Revenues Beat Estimates — Positive
PLUG Zacks Investment Research — May 13, 2025PLUG posts first-quarter 2025 results, wherein its revenues increase 11.1% year over year on growing electrolyzer deliveries and continued demand in material handling.
Where Food Comes From Q1 Profit Falls Amid Beef Market Headwinds — Negative
WFCF Zacks Investment Research — May 13, 2025WFCF posts lower Q1 earnings as beef market woes and avian flu weigh on revenues. Management highlights growth in retail labeling and upcycling.
